Infection of Hepatocytes With HCV Increases Cell Surface Levels of Heparan Sulfate Proteoglycans, Uptake of Cholesterol and Lipoprotein, and Virus Entry by Up-regulating SMAD6 and SMAD7.
The signaling molecule and transcriptional regulator SMAD6, which inhibits the transforming growth factor β signaling pathway, is required for infection of hepatocytes by hepatitis C virus (HCV). We investigated the mechanisms by which SMAD6 and another inhibitory SMAD (SMAD7) promote HCV infection in human hepatoma cells and hepatocytes.



We infected Huh7 and Huh7.5.1 cells and primary human hepatocytes with Japanese fulminant hepatitis-1 (JFH1) HCV cell culture system (HCVcc). We then measured HCV binding, intracellular levels of HCV RNA, and expression of target genes. We examined HCV entry in HepG2/microRNA (miR) 122/CD81 cells, which support entry and replication of HCV, were transfected these cells with small interfering RNAs targeting inhibitory SMADs to analyze gene expression profiles. Uptake of labeled low-density lipoprotein (LDL) and cholesterol was measured. Cell surface proteins were quantified by flow cytometry. We obtained liver biopsy samples from 69 patients with chronic HCV infection and 19 uninfected individuals (controls) and measured levels of syndecan 1 (SDC1), SMAD7, and SMAD6 messenger RNAs (mRNAs).



Small interfering RNA knockdown of SMAD6 blocked the binding and infection of hepatoma cell lines and primary human hepatocytes by HCV, whereas SMAD6 overexpression increased HCV infection. We found levels of mRNAs encoding heparan sulfate proteoglycans (HSPGs), particularly SDC1 mRNA, and cell surface levels of heparan sulfate to be reduced in cells after SMAD6 knockdown. SMAD6 knockdown also reduced transcription of genes encoding lipoprotein and cholesterol uptake receptors, including the LDL receptor (LDLR), the very LDLR, and the scavenger receptor class B member 1 in hepatocytes; knockdown of SMAD6 also inhibited cell uptake of cholesterol and lipoprotein. Overexpression of SMAD6 increased the expression of these genes. Similar effects were observed with knockdown and overexpression of SMAD7. In addition, HCV infection of cells increased the expression of SMAD6, which required the activity of nuclear factor-κB, but not transforming growth factor β. Liver tissues from patients with chronic HCV infection had significantly higher levels of SMAD6, SMAD7, and HSPG mRNAs than controls.



In studies of hepatoma cell lines and primary human hepatocytes, we found that infection with HCV leads to activation of nuclear factor-κB, resulting in increased expression of SMAD6 and SMAD7. Up-regulation of SMAD6 and SMAD7 induces the expression of HSPGs, such as SDC1, as well as LDLR, very LDLR, and the scavenger receptor class B member 1, which promote HCV entry and propagation, as well as cellular uptake of cholesterol and lipoprotein.
Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.
Fang
F
Zhang
Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.
Catherine
C
Sodroski
Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.
Helen
H
Cha
Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland. Electronic address: liqisheng@niddk.nih.gov.
Qisheng
Q
Li
Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland. Electronic address: jakel@bdg10.niddk.nih.gov.
T Jake
TJ
Liang
D055418:Bone Morphogenetic Protein 6 / Q000378:metabolism; D055419:Bone Morphogenetic Protein 7 / Q000378:metabolism; D002784:Cholesterol / Q000378:metabolism; D055785:Gene Knockdown Techniques; D056945:Hep G2 Cells; D016174:Hepacivirus / Q000502:physiology*; D019812:Heparan Sulfate Proteoglycans / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000235:genetics; D022781:Hepatocytes; D006801:Humans; D008074:Lipoproteins / Q000378:metabolism; D016328:NF-kappa B / Q000378:metabolism; D012333:RNA, Messenger / Q000032:analysis*; D034741:RNA, Small Interfering / Q000235:genetics; D012367:RNA, Viral / Q000032:analysis*; D011973:Receptors, LDL / Q000235:genetics; D015398:Signal Transduction; D051905:Smad6 Protein / Q000235:genetics* / Q000378:metabolism; D051906:Smad7 Protein / Q000235:genetics* / Q000378:metabolism; D053668:Syndecan-1 / Q000235:genetics / Q000378:metabolism; D014162:Transfection; D015854:Up-Regulation; D053586:Virus Internalization
C525816:BMP6 protein, human; C525819:BMP7 protein, human; D055418:Bone Morphogenetic Protein 6; D055419:Bone Morphogenetic Protein 7; D019812:Heparan Sulfate Proteoglycans; D008074:Lipoproteins; D016328:NF-kappa B; D012333:RNA, Messenger; D034741:RNA, Small Interfering; D012367:RNA, Viral; D011973:Receptors, LDL; C508241:SDC1 protein, human; C497802:SMAD6 protein, human; C497806:SMAD7 protein, human; D051905:Smad6 Protein; D051906:Smad7 Protein; D053668:Syndecan-1; C036053:VLDL receptor; D002784:Cholesterol
BMP; CTBP1; I-SMAD; Viral Entry
Nat Med. 2013 Jun;19(6):722-9
23708292
PLoS Pathog. 2014 May 22;10(5):e1004163
24852294
Gastroenterology. 2004 Nov;127(5 Suppl 1):S62-71
15508105
Int Orthop. 2013 Mar;37(3):529-41
23307015
Semin Cell Dev Biol. 2011 Dec;22(9):1012-8
22008724
J Biol Chem. 2013 Feb 1;288(5):3560-70
23255602
Mol Cell Biol. 2003 Sep;23(18):6646-61
12944489
Curr Opin Virol. 2012 Feb;2(1):14-9
22440961
Nature. 1997 Oct 9;389(6651):622-6
9335505
J Biol Chem. 2003 Oct 17;278(42):41003-12
12867431
Oncogene. 2006 Jul 6;25(29):4086-98
16491121
Nature. 2009 Feb 12;457(7231):882-6
19182773
Semin Liver Dis. 2013 Nov;33(4):358-68
24222093
Biochem Biophys Res Commun. 2003 Sep 5;308(4):858-65
12927798
Virology. 2005 Jan 20;331(2):407-17
15629783
Nat Med. 2012 Jan 08;18(2):281-5
22231557
J Virol. 2015 Apr;89(7):3846-58
25609801
Nature. 1996 Sep 12;383(6596):168-72
8774881
Nat Med. 2013 Jul;19(7):837-49
23836234
Science. 1996 Jan 26;271(5248):518-20
8560269
J Virol. 2011 Nov;85(22):12087-92
21917968
Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12766-71
10535997
Cold Spring Harb Perspect Biol. 2011 Jul 01;3(7):null
21690215
Nature. 2003 Oct 9;425(6958):577-84
14534577
Science. 1998 Oct 30;282(5390):938-41
9794763
PLoS One. 2014 Apr 21;9(4):e95550
24751902
Annu Rev Biochem. 1998;67:753-91
9759503
Mol Cell Biol. 2003 Dec;23(24):9081-93
14645520
Mol Biol Cell. 2010 Nov 15;21(22):4028-41
20861306
PLoS Pathog. 2015 May 29;11(5):e1004937
26023919
J Hepatol. 2011 Oct;55(4):920-32
21718726
Cell Signal. 2006 Sep;18(9):1482-91
16413747
J Virol. 2010 Jun;84(11):5751-63
20357091
Proc Natl Acad Sci U S A. 2013 Jun 25;110(26):10777-82
23754414
Cell. 1997 Jun 27;89(7):1165-73
9215638
J Virol. 2005 May;79(9):5774-85
15827192
Lancet Diabetes Endocrinol. 2014 Jun;2(6):513-26
24731656
Mol Biol Cell. 2003 Jul;14 (7):2809-17
12857866
Proc Natl Acad Sci U S A. 2016 Jul 5;113(27):7620-5
27298373
Nature. 2007 Apr 12;446(7137):801-5
17325668
Nat Med. 2011 May;17(5):589-95
21516087
Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16410-5
19717417
J Virol. 2013 Jun;87(12):6866-75
23576506
N Engl J Med. 2013 May 16;368(20):1907-17
23675659
Gastroenterology. 2010 Jun;138(7):2509-18, 2518.e1
20230822
Nature. 2007 Apr 26;446(7139):1030-7
17460664
J Virol. 1997 Apr;71(4):3244-9
9060688
Annu Rev Nutr. 2014;34:77-94
24995692
J Virol. 2012 Jul;86(13):7256-67
22532692
Hepatology. 2013 Apr;57(4):1333-42
23172780